First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril. 1988

M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
Department of Cardiology, Northwick Park Hospital, Harrow, Middlesex, England.

The reduction in blood pressure (BP) after the first dose and after 8 weeks of treatment with a new once-daily angiotensin converting enzyme (ACE) inhibitor, ramipril, was examined in 12 untreated hypertensive patients, using ambulatory intraarterial BP monitoring. The first period of monitoring began 24 hours before the first dose was given, and continued for 24 hours afterwards. A second 24-hour period of monitoring was carried out after 8 weeks of treatment, commencing immediately after the morning dose. Angiotensin II levels and serum drug levels were measured at 0, 2, 6 and 24 hours after the acute dose. BP decreased progressively from the first hour after the first dose, reached a maximum in the fifth hour (p less than 0.001) and then the effect diminished. The maximum reduction of systolic BP in any patient was 64 mm Hg, the minimum 4 mm Hg. Blood pressure was significantly (p less than 0.05) reduced throughout the 24 hours after dosing, with a mean daytime reduction of 13/12 mm Hg, and a mean nighttime reduction of 15/7 mm Hg. Angiotensin II levels were significantly (p less than 0.02) and maximally reduced by 2 hours after administration, but the reduction was no longer significant after 24 hours. Serum drug levels were also maximal 2 hours after administration. The trial population could be clearly divided into groups of good and poor responders on the basis of BP reduction. The angiotensin II levels were higher before treatment, and decreased further, in all patients with a good response than in those with a poor response.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001795 Blood Pressure Determination Techniques used for measuring BLOOD PRESSURE. Blood Pressure Determinations,Determination, Blood Pressure
D001952 Bridged-Ring Compounds Cyclic hydrocarbons that contain multiple rings which share one or more bridgehead connections. Bridged Compounds,Bridged Ring Compounds
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
January 1984, The American journal of cardiology,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
June 1989, Journal of human hypertension,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
August 2013, Journal of human hypertension,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
January 2008, Indian heart journal,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
January 1989, Journal of cardiovascular pharmacology,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
April 1987, The American journal of cardiology,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
April 1982, The Journal of practical nursing,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
January 1988, Arzneimittel-Forschung,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
January 1989, Journal of cardiovascular pharmacology,
M E Heber, and G S Brigden, and M P Caruana, and A Lahiri, and E B Raftery
February 1993, Arquivos brasileiros de cardiologia,
Copied contents to your clipboard!